CCA Summit Conference Correspondent

Targeted inhibition of specific drivers in the tumor immune microenvironment in genetically defined cholangiocarcinoma subtypes may represent a rational approach for therapeutic intervention.

Emerging biomarkers based on molecular features of biliary tract cancers may be useful to predict treatment response and further guide treatment modifications.

Positron emission tomography/magnetic resonance imaging have a role in cholangiocarcinoma when compared with conventional computed tomography or positron emission tomography alone.

HER2-targeted therapies show promising antitumor activity and manageable safety profile in biliary tract cancers.

A long-term survival benefit with radiation therapy in conjunction with chemotherapy or immunotherapy may be feasible in some patients with unresected intrahepatic cholangiocarcinomas.